Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Unikalmedi | Healthcare Services | 100.0% | 100th pct | 268 |
| Dimitri Mkheidzis Sakhe… | Healthcare Services | 19.1% | 76th pct | 268 |
| Aghmosavlet Sakartvelos… | Healthcare Services | 6.8% | 40th pct | 268 |
| Mezghvaurta Sameditsino… | Healthcare Services | 1.0% | 25th pct | 268 |
| Kutaisis #3 Samshobiaro… | Healthcare Services | -7.2% | 15th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Dimitri Mkheidzis Sakhe… | Kutaisis #3 Samshobiaro… | Aghmosavlet Sakartvelos… | Unikalmedi | Mezghvaurta Sameditsino… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 94.4% | 100.0% | 42.3% | 100.0% | 87.2% |
| EBITDA Margin | 19.1% | -7.2% | 6.8% | 100.0% | 1.0% |
| EBITDAR | 368 | -134 | 129 | 1,812 | 18 |
| EBITDAR Margin | 19.1% | -7.1% | 6.8% | 100.0% | 1.0% |
| EBIT Margin | 19.1% | -18.0% | 5.7% | 100.0% | -5.0% |
| Net Profit Margin | 11.4% | -28.8% | 6.0% | 100.0% | -5.7% |
| Operating Expense % of Sales | 75.3% | 107.2% | 35.5% | 0.0% | 86.2% |
| Returns | |||||
| Return on Assets (ROA) | 16.6% | -15.0% | 4.9% | 9.2% | -7.0% |
| Return on Equity (ROE) | 18.0% | -1660.0% | 5.5% | 32.1% | -33.5% |
| ROIC [EBIT / Invested Capital] | |||||
| 55.1% |
| -20.2% |
| 6.6% |
| 12.2% |
| -23.7% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 45.5% | 0.0% | 46.9% | 5.8% |
| Debt-to-Equity | 0.00x | 50.44x | 0.00x | 1.64x | 0.27x |
| Debt-to-EBITDA | 0.00x | N/A | 0.00x | 5.12x | 4.71x |
| Equity-to-Assets | 92.6% | 0.9% | 89.4% | 28.5% | 21.0% |
| Net Debt | -555 | 1,658 | -460 | 9,154 | 73 |
| Cash & Equivalents | 555 | 1 | 460 | 125 | 11 |
| Total Debt | N/A | 1,659 | N/A | 9,279 | 84 |
| Liquidity & working capital | |||||
| Current Ratio | 1.94x | 0.00x | 4.20x | 0.63x | 0.25x |
| Quick Ratio | 1.94x | 0.00x | 4.20x | 0.63x | 0.25x |
| Cash Ratio | 5.67x | 0.00x | 2.56x | 0.16x | 0.01x |
| Total Current Assets | 190 | 0 | 755 | 486 | 278 |
| Total Current Liabilities | 98 | 851 | 180 | 767 | 1,106 |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Trade Receivables | N/A | 1,301 | 158 | 7,546 | 240 |
| Trade Payables | 8 | 682 | 76 | 2,238 | 94 |
| Net Working Capital | 92 | -851 | 575 | -281 | -828 |
| Net Working Capital % of Revenue | 4.8% | -44.9% | 30.4% | -15.5% | -45.9% |
| Trade Working Capital | -8 | 620 | 82 | 5,308 | 146 |
| Trade Working Capital % of Revenue | -0.4% | 32.7% | 4.3% | 293.0% | 8.1% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | N/A | 1.46x | 11.96x | 0.24x | 7.52x |
| Days Sales Outstanding (DSO) | N/A | 250.6 | 30.5 | 1520.0 | 48.5 |
| Payables Turnover | 13.92x | N/A | 14.29x | N/A | 2.45x |
| Days Payable Outstanding (DPO) | 26.2 | N/A | 25.5 | N/A | 149.0 |
| Cash Conversion Cycle | -26.2 days | 250.6 days | 5.0 days | 1520.0 days | -100.5 days |
| Asset Turnover | 1.46x | 0.52x | 0.81x | 0.09x | 1.24x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 1,928 | -51 | 116 | 118 | 134 |
| Free Cash Flow (OCF − Capex proxy) | 1,928 | -51 | 116 | 118 | 133 |
| Cash Conversion (OCF / EBITDA) | 523.6% | N/A | 90.1% | 6.5% | 753.2% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |